TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
1 hedge funds and large institutions have $80 invested in TRACON Pharmaceuticals, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 28 closing their positions.
97% less funds holding
Funds holding: 29 → 1 (-28)
100% less capital invested
Capital invested by funds: $1.39M → $80 (-$1.39M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 28
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
-$194K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$176K |
| 3 |
Squarepoint
New York
|
-$167K |
| 4 |
Renaissance Technologies
New York
|
-$129K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$123K |
TCON Hedge Fund Activity: Q2 2024 in Review
1 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q2 2024, worth a combined $80 — down 100% from $1.39M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of TCON and 0 opened new positions — a net loss of 28 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was LPL Financial, exiting entirely with an estimated $194K sold.
- 1 institutional investor held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q2 2024, down from 29 in Q1 2024.
- Funds reported $80 of TRACON Pharmaceuticals, Inc. Common Stock stock for Q2 2024, down 100% quarter-over-quarter.
- 0 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q2 2024 and 28 closed out, a net change of -28 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q2 2024 was LPL Financial, an estimated $194K sold.
Based on aggregated 13F filings for Q2 2024.